The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a new subcutaneous route of administration for Saphnelo (anifrolumab), used as an add-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback